Symbols

HUMA

Humacyte·NASDAQ

--(--)

HUMA fundamentals

HUMA Q4 2025 Earnings

Humacyte (HUMA) released its earnings on Mar 27, 2026: revenue was 467.00K (YoY --), missed estimates; EPS was -0.13 (YoY +18.75%), beat estimates.

Revenue / YoY

467.00K

EPS / YoY

-0.13

+18.75%

Report date

Mar 27, 2026

HUMA Earnings Call Summary for Q4,2025

Symvess Adoption Accelerating: 27 U.S. hospitals ordered, 70% VAC approval rate, and $1.475M Saudi purchase highlight expanding reach.
Clinical Excellence: 82.5% limb salvage and no failures in trauma trials validate Symvess as life-saving.
Financial Resilience: $50.5M cash, $77.5M credit facility, and reduced R&D/SG&A expenses support growth.
Pipeline Momentum: ATEV interim results in Q2 and CTEV trials in late 2026 position for future revenue streams.

Earnings

EPS

Revenue

Revenue & Expenses

HUMA has released its 2025 Q4 earnings report, with revenue of 467.00K, reflecting a YoY change of NaN%, and net profit of -24.80M, showing a YoY change of -18.45%. The Sankey diagram below clearly presents HUMA's revenue sources and cost distribution.

Key Indicators

Humacyte (HUMA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Humacyte (HUMA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Humacyte (HUMA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Humacyte (HUMA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown